Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Google Secures Pentagon AI Deal for Classified Projects 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
PLYMOUTH, Minn., April 20, 2017 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced the Company plans to participate in the 42nd Annual Health Care Conference hosted by Deutsche Bank in Boston, MA.
Entellus Medical’s management is scheduled to present on Thursday, May 4, 2017 at 11:20am ET. Interested parties can access the live audio webcast at http://www.entellusmedical.com. An archived presentation will be available on the website.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of patients. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, as well as adult patients with persistent Eustachian tube dysfunction. The Entellus Medical platform of products provides effective and easy-to-use solutions intended to help simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical’s core product lines, XprESS™ ENT Dilation System, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify treatment based in the operating room. Entellus Medical is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
Contact: Lynn Pieper Lewis 415-937-5402 [email protected]
